DHFR and tuberculosis: Our laboratory for Novel Drug Design and Discovery has been conducting studies on the potential of dihydrofolate reductase (DHFR) and enoyl-acyl carrier protein (enoyl-ACP) reductase as molecular targets for anti-tuberculosis (anti-TB) therapies.